114 -3 (31/3) 2020 — Ju Seunghwan, Shamansurova Z.M., — METABOLIC CONNECTIONS IN DM PATIENTS ON HEMODIALYSIS

METABOLIC CONNECTIONS IN DM PATIENTS ON HEMODIALYSIS

Ju Seunghwan. -Tashkent Pediatric Medical Institute,-Republican Specialized Scientific Practical Medical Center of Endocrinology after name of Acad. Turakulov Y.Kh., Health Care Ministry of Uzbekistan, -Institute of Biophysics and Biochemistry at UzNU, Tashkent.

Shamansurova Z.M. -Tashkent Pediatric Medical Institute,-Republican Specialized Scientific Practical Medical Center of Endocrinology after name of Acad. Turakulov Y.Kh., Health Care Ministry of Uzbekistan, -Institute of Biophysics and Biochemistry at UzNU, Tashkent.

Khalikov A.Y. -Tashkent Pediatric Medical Institute,-Republican Specialized Scientific Practical Medical Center of Endocrinology after name of Acad. Turakulov Y.Kh., Health Care Ministry of Uzbekistan, -Institute of Biophysics and Biochemistry at UzNU, Tashkent.

Ismailov S.I. -Tashkent Pediatric Medical Institute,-Republican Specialized Scientific Practical Medical Center of Endocrinology after name of Acad. Turakulov Y.Kh., Health Care Ministry of Uzbekistan, -Institute of Biophysics and Biochemistry at UzNU, Tashkent.

Resume

Background. About 80% of kidneys insufficiency/ develops due to Diabetes Mellitus (DM). Patients with end stage of renal disease (ESRD) presents wide range of biochemical abnormalities and requires hemodialysis. Glycemic level is critical for hemodialysis outcome. We proposed that glucose fluctuation on hemodialysis linked to blood biochemical abnormalities.

Material and methods. Total in 45 patients, 15 with DM1 and 21 with DM2, admitted to hemodialysis unit at the Republican Specialized Scientific Practical Medical Center of Endocrinology were observed. Patient blood pressure, body weight, MDRD, blood glucose, blood biochemistry had been assessed.

Results. 46 patients with ESRD on hemodialysis differs by average age (35.9 vs 64.6 years old), body weight (70.32 kg vs 87.82kg), average DM duration were comparable (19.6 vs 20.79). There were not found any differences in systolic and diastolic pressure, blood serum enzymes ALT, AST levels, serum creatinine and MDRD between DM1 and DM2 groups. About 40% of DM1 and 64% of DM2 patients with ESRD on hemodialysis have total Hb level below 90 mg%. However, when patients distributed according to total hemoglobin level Hb<90 and Hb>90 there were significant difference in blood serum albumin (in DM1 Hb>90 group 42.69±0.88 g/L vs DM2 Hb>90 group 39.5±1.29 g/L, p<0.05), blood serum sodium level (in DM1 Hb<90 group 128±2.4 mmol/L vs DM2 Hb<90 group 134.9±2.11 mmol/L), phosphates (DM1 Hb>90 group 2.03±0.07 mmol/L vs DM2 Hb>90 group 1.66±0.07 mmol/L) levels. Comparing glycemia before and after hemodialysis were not showed any significant differences between DM1 and DM2 groups. However, distribution the groups according to Hb level showed lower glycemia in Hb<90 DM2 group before (in 1.4 times, p>0.05) and after (in 1.4 times, p<0.05) hemodialysis, which were not seen in DM1 group. We concluded that DM2 group especially those with Hb<90 should be aware hypoglycemia during hemodialysis. Since we found relationship of some parameters with Hb level correlational analysis were performed with all studied parameters. Interestingly, that total Hb showed well correlation link with glycemia before and after hemodialysis in both DM1 and DM2 groups, whereas in DM1 patients Hb correlation were shown with DAD, AST, Potassium and sodium level, whereas in DM2 group correlation Hb were shown with body weight and MDRD.

Conclusion. To determine risk of hypoglycemia and outcome in DM patients checking blood total hemoglobin level is recommended, if it is lower than 90 mg% be aware hypoglycemia in DM2 patients.

Key words: Diabetes Mellitus, hemodialysis.

First page

476

Last page

480

For citation: Ju Seunghwan, Shamansurova Z.M Khalikov A.Y., Ismailov S.I., Metabolic connections in dm patients on hemodialysis//New Day in Medicine 3(31)2020 476-480 https://cutt.ly/8xFnsaA

List of References

  1. Atlas, I. D. F. D. (2019). Idf diabetes atlas..
  2. Mooyaart, A. (n.d.). Diabetic nephropathy Pathology, genetics and carnosine metabolism. In Diabetic nephropathy.
  3. Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic kidney disease: Challenges, progress, and possibilities. Clinical Journal of the American Society of Nephrology
  4. Lim, A. K. H. (2014). Diabetic nephropathy – Complications and treatment. International Journal of Nephrology and Renovascular Disease
  5. MOH India. (2010). Guidelines for Dialysis Centre.
  6. Tsur, N., Menashe, I., & Haviv, Y. S. (2019). Risk Factors Before Dialysis Predominate as Mortality Predictors in Diabetic Maintenance Dialysis patients. Scientific Reports
  7. Sulaiman, M. K. (2019). Diabetic nephropathy: Recent advances in pathophysiology and challenges in dietary management. Diabetology and Metabolic Syndrome
  8. Ritz, E., Rychlik, I., Locatelli, F., & Halimi, S. (1999). End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. American Journal of Kidney Diseases,
  9. Gumina, S., Candela, V., & Passaretti, D. (2016). Diabetes. Rotator Cuff Tear: Pathogenesis, Evaluation and Treatment,
  10. Vuji?i?, B., Turk, T., Crn?evi?-Orli?, ?., ?or?evi?, G., & Ra?ki, S. (2012). Pathophysiology and Complications of Diabetes Mellitus,
  11. Sbrignadello, S., Pacini, G., & Tura, A. (2016). Determination of glucose levels during dialysis treatment: Different sensors and technologies. Journal of Sensors, 2016.
  12. Шамаисурова 3.M., Туракулов Я.Х., Ким А.А.. Джураева Г.Т., Ахмедова М.Х., Акбаров 3.C. Изучение связывания инсулина с эритроцитами при сахарном диабете. Журнал теоретической и клинической медицины. 2006, N3, C.71-75.
  13. Акбаров 3.C., Касымов У.А.. Шамаисурова 3.M. Диабети­ческая нефропатия: классификация, диагностика. лечение. Ташкент’. 2000. 22с.
  14. Мерков А.М.. Поляков Л.Е. Санитарная статистика (пособие для врачей).- Л.: Mедицина. 1974. 384 с.
  15. Шамаисурова 3М. Мухамедова ФА, Цой АГ. Ташманова АБ. Алиева АВ. Ахрарова нA. нарушение активности натрий-калиевой АТФ азы у пациектов с сахарным диабетом. Сахарный Диабет. 2009. N2. С.55-57.
  16. Шамаисурова 3.М.. Алиева А.В.. Ташманова А.Б.. Ахрарова Н.А.. Цой А.Г.. Мухамедова Ф.А.. Кулимбетов М.Т. Изме- нение активности натрий-калиевой АТФазы и сиалидазы эритроцитов у крыс с экспериментальным диабетом. ожи­рением. гиперинсулинемией. Проблемы биологии и меди­цины №2-2011г. стр.68-72.
114-476-480-3-31-2020-

file

download